Heparin News and Research

RSS

Heparin, a highly-sulfated glycosaminoglycan, is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. It can also be used to form an inner anticoagulant surface on various experimental and medical devices such as test tubes and renal dialysis machines. Pharmaceutical grade heparin is derived from mucosal tissues of slaughtered meat animals such as porcine (pig) intestine or bovine (cow) lung.

Study Links Adenovirus Infection With a Rare Blood Clotting Disorder

Platelets, or thrombocytes, are specialized cellular fragments that form blood clots when we get scrapes and traumatic injuries. Viral infections, autoimmune disease, and other conditions can cause platelet levels to drop throughout the body, termed thrombocytopenia.

11 Aug 2023

New Bio-Inspired Molecules can Enhance Bone Regeneration in Mice

People's ability to regenerate bones declines with age and is further decreased by diseases such as osteoporosis.

2 May 2023

Mortality of newborns on ECMO linked with red blood cell transfusion volume

Newborns in respiratory failure who require the life-sustaining support of ECMO also require transfusion of red blood cells. But a new study indicates that the higher volume of these oxygen-carrying blood cells the babies receive, the higher their mortality rate.

15 Feb 2022

Healthy sleep pattern alleviates some of the symptoms of Alzheimer’s disease

According to research, the brain’s capacity to clear a protein closely associated with Alzheimer’s disease is tied to the circadian cycle.

14 Feb 2022

Emerging variants of COVID-19 could be treated with a new anticoagulant drug

The capacity of the COVID-19 virus’s spikes to bind to human cells may be hampered by molecules from the same family as the anticoagulant medication heparin.

9 Jul 2021

New high-throughput system for testing drug candidates to treat neurodegenerative diseases

On the basis of a license agreement with the German Center for Neurodegenerative Diseases (DZNE) and the Leibniz Institute of Polymer Research Dresden (IPF), the Dresden-based start-up "Neuron-D GmbH" is developing a high-throughput system for testing drug candidates to treat neurodegenerative diseases.

19 Mar 2021